The U.S. Food and Drug Administration approved Nereus (tradipitant) from Vanda Pharmaceuticals, marking the first new prescription treatment for motion sickness in more than four decades. Approval was supported by three pivotal studies, including two phase III trials conducted in real-world shipboard settings. Vanda plans a commercial launch in early 2026. The decision triggers immediate commercial and regulatory consequences: Vanda’s shares jumped sharply on the news, and the company will move to scale manufacturing and market access efforts. For clinicians and hospital pharmacies, Nereus offers a new oral antiemetic option targeting the neurokinin-1 receptor. The approval highlights the FDA’s willingness to clear late-stage, symptom-focused therapies when robust, pragmatic trial data exist.